CKD Overview & Staging

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for more than 3 months, with implications for health. It is staged by estimated glomerular filtration rate (eGFR) and albuminuria:

  • Stage 1: eGFR ≥90 mL/min with markers of kidney damage (albuminuria); kidney function normal but damage present
  • Stage 2: eGFR 60–89; mildly reduced; often asymptomatic
  • Stage 3a/3b: eGFR 30–59; moderately reduced; anemia and bone disease begin; dietary management critical
  • Stage 4: eGFR 15–29; severely reduced; preparation for renal replacement therapy
  • Stage 5 (End-Stage Renal Disease): eGFR <15; dialysis or transplantation required

Epidemiology: CKD affects ~15% of US adults (37 million people); 90% are unaware of their diagnosis — screening is critical in at-risk populations (diabetics, hypertensives, over 60). CKD significantly increases cardiovascular mortality — most CKD patients die from cardiovascular events before reaching dialysis.

Key tests: eGFR (from serum creatinine and cystatin C), urine albumin-to-creatinine ratio (ACR), blood pressure, potassium, bicarbonate, hemoglobin, and phosphate.

Major Risk Factors

  • Diabetes mellitus: The leading cause of CKD and ESRD; diabetic nephropathy affects 20–40% of diabetics; hyperglycemia causes glomerular hyperfiltration, basement membrane thickening, and podocyte loss; HbA1c control below 7% reduces CKD progression
  • Hypertension: Second most common cause; systemic and glomerular hypertension damages nephrons progressively; target blood pressure below 130/80 mmHg in CKD — the most evidence-supported intervention
  • Obesity: Obesity-related glomerulopathy — visceral fat promotes glomerular hyperfiltration, podocyte stress, and inflammation; independent CKD risk factor even without diabetes or hypertension
  • NSAIDs and analgesics: Regular NSAID use causes renal prostaglandin inhibition, reducing renal perfusion; analgesic nephropathy from chronic high-dose use; greatest risk in those with pre-existing CKD, elderly, and dehydrated patients
  • Contrast nephropathy: Iodinated contrast media causes acute kidney injury — risk mitigated by pre-hydration with IV saline and using lowest contrast volume necessary
  • Recurrent kidney stones: Calcium oxalate stones cause progressive renal scarring with each obstructive episode
  • Family history: APOL1 gene variants significantly increase CKD risk in individuals of African ancestry

Dietary Management in CKD

Diet is one of the most evidence-supported tools for slowing CKD progression:

  • Protein restriction: Low-protein diets (0.6–0.8g/kg/day) reduce glomerular filtration pressure and slow CKD progression; most beneficial in stages 3–4; very low protein diets (0.3g/kg with keto acid supplementation) show further benefit; must balance protein restriction against malnutrition risk
  • Phosphorus management: Phosphorus accumulates in CKD and drives secondary hyperparathyroidism and cardiovascular calcification; limit high-phosphorus foods (processed foods with phosphate additives, dark colas, dairy excess); organic phosphorus from plant foods is less bioavailable than inorganic additives
  • Potassium management: Hyperkalemia is a serious risk in advanced CKD; limit high-potassium foods (bananas, potatoes, tomatoes, oranges) in stages 3b–5; dietary potassium restriction should be individualized based on serum levels
  • Sodium restriction: Below 2g sodium/day reduces blood pressure, proteinuria, and edema; supports antihypertensive medication efficacy; avoidance of processed foods is the most practical approach
  • Plant-based diet: Increasing evidence that plant-predominant diets slow CKD progression — produce less sulfuric acid than animal protein, reduce phosphorus load (lower bioavailability), and improve gut microbiome; also reduces cardiovascular risk
  • Hydration: Adequate fluid intake maintains urine flow and prevents stone formation and UTIs; 2–3L/day appropriate in early CKD without edema; restriction required in advanced CKD with fluid overload

Medication Evidence for CKD

  • ACE inhibitors and ARBs: First-line for CKD with proteinuria and/or diabetes; reduce intraglomerular pressure; reduce proteinuria by 30–40%; slow CKD progression independent of blood pressure effect; target urine ACR below 300 mg/g; avoid combination (dual blockade increases AKI risk)
  • SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin): Transformative renal protective drugs; CREDENCE and DAPA-CKD trials showed 30–40% reduction in CKD progression and kidney failure regardless of diabetes status; now recommended as standard of care in CKD with proteinuria; mechanism: reduce glomerular hyperfiltration via tubuloglomerular feedback
  • GLP-1 receptor agonists (semaglutide, liraglutide): Reduce kidney inflammation and fibrosis via FLOW trial data; reduce CKD progression in diabetic patients; additional benefit via weight loss reducing obesity-related glomerulopathy
  • Blood pressure management: Target below 130/80 mmHg in CKD; preferred agents: ACE inhibitors/ARBs (also renoprotective), calcium channel blockers (renal safe); avoid NSAIDs; thiazide diuretics less effective when eGFR below 30
  • Bicarbonate supplementation: Metabolic acidosis in CKD accelerates progression; sodium bicarbonate supplementation to maintain serum bicarbonate above 22 mmol/L slows CKD progression in RCTs

Prevention Strategies

  • Diabetes control: HbA1c below 7% is the most important preventive measure for diabetic nephropathy; SGLT2 inhibitors provide dual metabolic and renoprotective benefit
  • Blood pressure control: Consistent BP below 130/80 mmHg prevents hypertensive nephrosclerosis; home blood pressure monitoring improves control
  • Avoid nephrotoxins: Minimize NSAID use — use paracetamol/acetaminophen instead; avoid contrast media in at-risk patients; be cautious with aminoglycoside antibiotics; limit herbal preparations with renal toxicity (aristolochic acid in traditional Chinese herbs)
  • Maintain healthy weight: Obesity-related nephropathy is a growing cause of CKD; 5–10% weight loss reduces proteinuria and glomerular hyperfiltration
  • Kidney stone prevention: Adequate hydration (2.5L/day urine output target); specific dietary adjustments by stone type (calcium oxalate: reduce sodium, maintain normal calcium intake; uric acid stones: reduce animal protein, alkalinize urine)
  • Smoking cessation: Smoking accelerates CKD progression; increases proteinuria; independently associated with ESRD risk
  • Screening: Annual eGFR and urine ACR in all people with diabetes, hypertension, obesity, or family history of kidney disease

Supplement Cautions in Kidney Disease

People with CKD must exercise significant caution with supplements — many are eliminated renally and can accumulate to toxic levels:

  • Vitamin C: High doses (>250mg/day) increase oxalate load — risk of calcium oxalate stone formation and oxalate nephropathy in CKD; limit to dietary sources
  • Magnesium: Renally excreted; can accumulate in CKD causing hypermagnesemia; use with caution in stages 3+ and only if deficient
  • Potassium-containing supplements: Potentially dangerous in advanced CKD (stages 3b–5); always check potassium levels before supplementing
  • Protein supplements: High-dose protein powders worsen CKD progression; protein restriction is therapeutic in CKD stages 3–4
  • NSAIDs (including ibuprofen as OTC): Most nephrotoxic common supplement/OTC drug; even short-term use in dehydrated states causes acute kidney injury in CKD
  • Vitamin D: Required in CKD as kidney activation of vitamin D (1-hydroxylation) is impaired; active form (calcitriol or alfacalcidol) may be prescribed; monitor calcium levels
  • Safe supplements in early CKD: Omega-3 fatty acids (reduce proteinuria), bicarbonate (if acidotic), iron (for renal anemia), and erythropoietin-stimulating agents (prescribed) all have evidence-based roles

Frequently Asked Questions

Early CKD is typically asymptomatic — which is why screening is critical. When symptoms do appear they include: fatigue (from anemia of chronic kidney disease), swelling in ankles and feet (fluid retention), changes in urination frequency or appearance (foamy urine indicating protein), high blood pressure that is difficult to control, and back or flank pain. Blood tests (eGFR, creatinine) and urine tests (albumin-to-creatinine ratio) detect CKD long before symptoms develop.

CKD is generally not reversible once established, but progression can be significantly slowed or stabilized. Some causes — such as acute kidney injury, obstruction, or medication toxicity — are reversible if treated promptly. SGLT2 inhibitors have shown remarkable ability to stabilize and in some cases slightly improve eGFR in early stages. Early intervention, blood pressure control below 130/80 mmHg, and ACE inhibitor/ARB therapy are the most evidence-based approaches to preventing progression.

In established CKD: high-phosphorus foods (processed foods with phosphate additives, dark colas, excess dairy), high-potassium foods (bananas, potatoes, oranges — in advanced stages), high-sodium foods (processed and packaged foods), and excessive animal protein. For general kidney health prevention: regular NSAID use is the most impactful dietary risk — even OTC ibuprofen is significantly nephrotoxic, particularly in dehydrated or elderly individuals.

In healthy adults and early CKD (stages 1–2), 2–3L fluid/day maintains urine flow, reduces kidney stone risk, and supports waste elimination. In advanced CKD (stages 4–5) with fluid retention or reduced urine output, fluid restriction may be required — always follow physician guidance. For kidney stone prevention, the target is 2.5L/day urine output, which typically requires drinking 2.5–3L depending on climate and activity level.

In people with normal kidney function, high protein intake does not cause CKD — but may modestly accelerate progression in those with pre-existing kidney disease. In established CKD stages 3–4, protein restriction (0.6–0.8g/kg/day) is a key therapeutic intervention that slows disease progression. High-dose protein powders (60–120g/day above dietary intake) are inappropriate for people with any degree of reduced kidney function and should be avoided.

Research Summary

CKD is common, largely preventable, and manageable with early intervention. SGLT2 inhibitors, ACE inhibitors, blood pressure control, and dietary modification are the cornerstones of evidence-based CKD management.

  • Evidence strength: Strong (4/5)
  • Prevalence: 15% of US adults; 90% unaware
  • Top modifiable risks: Diabetes, hypertension, obesity, NSAID use
  • Transformative medication: SGLT2 inhibitors — 30–40% CKD progression reduction
  • Dietary: Protein restriction + low sodium + plant-forward in CKD stages 3–4
  • Most harmful common OTC: NSAIDs — nephrotoxic even at standard doses in at-risk groups
⚠️ Medical Disclaimer: This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health decisions.

References

All studies cited are peer-reviewed. DOI and PubMed links open in a new tab.

  1. 1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105(4S), S117–S314. doi:10.1016/j.kint.2023.10.018 PMID:38490803
  2. 2. Perkovic V, Jardine MJ, Neal B, et al. (CREDENCE Trial Investigators) (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380(24), 2295–2306. doi:10.1056/NEJMoa1811744 PMID:30990260
  3. 3. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. (DAPA-CKD Trial Committees) (2020). Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 383(15), 1436–1446. doi:10.1056/NEJMoa2024816 PMID:32970396
  4. 4. Kalantar-Zadeh K, Fouque D (2017). Nutritional Management of Chronic Kidney Disease. New England Journal of Medicine, 377(18), 1765–1776. doi:10.1056/NEJMra1700312 PMID:29091561
  5. 5. Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G (2017). A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney International, 91(5), 1224–1235. doi:10.1016/j.kint.2016.12.013 PMID:28216249
  6. 6. Ruggenenti P, Perna A, Loriga G, et al. (2005). Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet, 365(9463), 939–946. doi:10.1016/S0140-6736(05)71082-5 PMID:15766996
  7. 7. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009). Bicarbonate supplementation slows progression of CKD and improves nutritional status. Journal of the American Society of Nephrology, 20(9), 2075–2084. doi:10.1681/ASN.2008111205 PMID:19608703
  8. 8. Whelton PK, Carey RM, Aronow WS, et al. (2018). 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology, 71(19), e127–e248. doi:10.1016/j.jacc.2017.11.006 PMID:29146535